PanGenX creates innovative solutions for drug development and personalized therapy by offering advanced analytics powered by semantically linked clinical and pharmacogenomic data.
PanGenX was founded in 2010 on the belief that current treatment outcomes can be improved through effective use of clinical genetic data. The company, based in Newton Center and just a few miles from Boston, sits in the heart of a community of world experts in medicine, science, and pharmacology. With a mission to create innovative solutions for drug development and personalized therapy, PanGenX utilizes semantic web technology and pharmacogenomics knowledge to identify the most effective treatments for individual patients and their representative sub-populations.
The Semantic Web technology integrates different content, data sources and information systems, and claims a growing interest in biological and clinical fields. This technology enables computers to “understand” and respond to complex human requests by semantically structuring relevant information sources within a given knowledge domain. PanGenX is using Semantic Web technology to link information from multiple public databases with proprietary clinical, genetic and drug data, to discover innovative pharmaceutical insights invaluable to its customers.
PanGenX tailors its solutions for each therapeutic area to the needs of each customer using pharmacogenomics knowledge delivered by the semantic web technology.
Pharmacogenetics refers to genetic variation (e.g. single nucleotide polymorphisms), which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects. Recent improvement in cost-efficiency of new generation sequencing technology, combined with a growing body of data from whole genome association studies and individual patient genotyping data, creates a valuable baseline for establishing a solid understanding the association of genetic variation with drug response.
Our Population Segmentation approach uses statistical evidence to discover the association between drug response and observed polymorphism(s) within certain ethnic groups and sub-populations. PanGenX currently focuses on improving Type II diabetes treatment outcomes and plans to expand its therapeutic portfolio over time. Patient outcome improvement for diabetes and other disease areas holds the promise of reducing, both directly and indirectly, the escalating healthcare costs associated with each disease. PanGenX works with therapeutic companies to accelerate clinical testing, approval, and adoption of promising new treatment alternatives. In the future, these evidence based clinical insights will become an integral part of point-of-care clinical decision support systems for physicians and other healthcare providers.